EA201591737A1 - SHIPPING SDF-1 FOR THE TREATMENT OF CHEMISTRATED TISSUE - Google Patents
SHIPPING SDF-1 FOR THE TREATMENT OF CHEMISTRATED TISSUEInfo
- Publication number
- EA201591737A1 EA201591737A1 EA201591737A EA201591737A EA201591737A1 EA 201591737 A1 EA201591737 A1 EA 201591737A1 EA 201591737 A EA201591737 A EA 201591737A EA 201591737 A EA201591737 A EA 201591737A EA 201591737 A1 EA201591737 A1 EA 201591737A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- subject
- sdf
- methods
- treating
- left ventricular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Medicinal Preparation (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
Abstract
Представлены методы лечения кардиомиопатии субъекта путем введения напрямую или локального экспрессирования в ослабленную, ишемическую и/или периинфарктную область миокардиальной ткани субъекта количества фактора, полученного из стромальных клеток (SDF-1), эффективного для возникновения функционального улучшения по меньшей мере одного из следующих параметров: объем левого желудочка, область левого желудочка, размер левого желудочка, сердечная функция, тест 6-минутной ходьбы или функциональная классификации Ассоциации сердца Нью-Йорка (NYHA). Также представлены методы лечения критической ишемии конечности у субъекта путем введения плазмиды ДНК, кодирующей человеческий SDF-1 путем прямой инъекции в поврежденную конечность.Methods of treating a subject’s cardiomyopathy by administering directly or locally expression to a weakened, ischemic and / or peri-infarction region of a subject’s myocardial tissue are presented an amount of a factor derived from stromal cells (SDF-1) that is effective for causing a functional improvement of at least one of the following parameters: volume left ventricle, left ventricular region, left ventricular size, cardiac function, 6-minute walk test or functional classification of the New York Heart Association (NYHA). Also provided are methods for treating critical limb ischemia in a subject by introducing a DNA plasmid encoding human SDF-1 by direct injection into an injured limb.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794742P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/029948 WO2014145225A1 (en) | 2013-03-15 | 2014-03-15 | Sdf-1 delivery for treating ischemic tissue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201591737A1 true EA201591737A1 (en) | 2016-01-29 |
| EA031308B1 EA031308B1 (en) | 2018-12-28 |
Family
ID=51537912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591737A EA031308B1 (en) | 2013-03-15 | 2014-03-15 | Sdf-1 delivery for treating ischemic tissue |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2970941A4 (en) |
| JP (1) | JP6461085B2 (en) |
| KR (1) | KR20160005021A (en) |
| CN (1) | CN105264071B (en) |
| EA (1) | EA031308B1 (en) |
| IL (1) | IL240710A0 (en) |
| WO (1) | WO2014145225A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4299119A1 (en) * | 2022-06-29 | 2024-01-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Therapeutic applications based on the inhibition of g protein-coupled receptor 182 (gpr182) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| JP5856059B2 (en) * | 2009-08-28 | 2016-02-09 | ザ クリーブランド クリニック ファウンデーション | SDF-1 delivery for treating ischemic tissue |
-
2014
- 2014-03-15 JP JP2016503290A patent/JP6461085B2/en active Active
- 2014-03-15 EA EA201591737A patent/EA031308B1/en not_active IP Right Cessation
- 2014-03-15 EP EP14762452.2A patent/EP2970941A4/en not_active Withdrawn
- 2014-03-15 KR KR1020157028804A patent/KR20160005021A/en not_active Application Discontinuation
- 2014-03-15 WO PCT/US2014/029948 patent/WO2014145225A1/en active Application Filing
- 2014-03-15 CN CN201480017356.4A patent/CN105264071B/en active Active
-
2015
- 2015-08-20 IL IL240710A patent/IL240710A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016515818A (en) | 2016-06-02 |
| JP6461085B2 (en) | 2019-01-30 |
| CN105264071B (en) | 2020-05-19 |
| CN105264071A (en) | 2016-01-20 |
| KR20160005021A (en) | 2016-01-13 |
| IL240710A0 (en) | 2015-10-29 |
| EA031308B1 (en) | 2018-12-28 |
| WO2014145225A1 (en) | 2014-09-18 |
| EP2970941A4 (en) | 2016-11-30 |
| EP2970941A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012002610A (en) | Sdf-1 delivery for treating ischemic tissue. | |
| CY1123688T1 (en) | METHODS OF THERAPEUTIC TREATMENT OF TUMORS USING CD3XCD20 AMPHIID ANTIBODY | |
| PH12020500555A1 (en) | Esketamine for the treatment of depression | |
| MX2022006107A (en) | Methods and compositions for dosing in adoptive cell therapy. | |
| EA201800199A1 (en) | APPLICATION OF AKKERMANSIA MUCINIPHILA FOR THE TREATMENT OF METABOLIC DISORDERS, INCREASE ENERGY CONSUMPTION AND WEIGHT REDUCTION, COMPOSITIONS, MEDICINE | |
| MX2018005332A (en) | Materials and methods for treatment of glycogen storage disease type 1a. | |
| AR095054A1 (en) | ELECTROHYDRAULIC GENERATOR (EH) DEVICE FOR FAST PULSE SHOCK WAVES, AND METHODS FOR MEDICAL AND COSMETIC TREATMENTS | |
| EA201891009A1 (en) | CONNECTIONS OF PYRIMIDINDION | |
| EA201391701A1 (en) | NAZAL TESTOSTERONE GELS WITH CONTROLLED SHIPPING, METHODS OF PORNASAL INTRODUCTION AND PRELIMINARY FILLED MULTI-APPLICATED APPLICATOR SYSTEMS FOR PORNINAL INTRODUCTION | |
| UA99953C2 (en) | Treatment of dyspnea associated with acute heart failure | |
| PE20121520A1 (en) | PHARMACEUTICAL FORMULATION INCLUDING RANOLAZINE AND DRONEDARONE IN THE TREATMENT OF ATRIAL FIBRILLATION | |
| CL2018001677A1 (en) | Treatment of fabry disease in patients not treated and previously treated with ert | |
| EA202090564A1 (en) | METHODS FOR STRENGTHENING AND / OR STABILIZING THE CARDIAC FUNCTION IN PATIENTS WITH FABRIC DISEASE | |
| CY1120793T1 (en) | METHODS OF TREATMENT OF HAIR CONDITIONS | |
| BR112014012054A2 (en) | deferiprone treatment methods | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| RU2018107704A (en) | MEDICINE CONTAINING ATTRACTANT OF FAT STEM CELLS TO IMPROVE THE FRUIT OR AGING OF THE SKIN CAUSED BY THE FORMATION OF DERMAL CAVITIES | |
| EA201591737A1 (en) | SHIPPING SDF-1 FOR THE TREATMENT OF CHEMISTRATED TISSUE | |
| PE20110066A1 (en) | DRONEDARONE FOR THE PREVENTION OF CARDIOVERSION | |
| MX2017000082A (en) | Compositions and methods to improve adoptive cell therapies. | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| EA201690903A1 (en) | TREATMENT GLAUCOMA USING LAQUINIMODE | |
| EA201500137A1 (en) | METHOD OF TREATING ADDICTION | |
| EA201592058A1 (en) | APPLICATION OF LANDIOLOL HYDROCHLORIDE IN LONG-TERM TREATMENT OF TACHIHARITHMIA | |
| WO2015070050A8 (en) | Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |